- Home
- NB vs FTRE Comparison
NB vs FTRE Comparison
Compare NB & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- FTRE
- Stock Information
- Founded
- NB 1987
- FTRE 1996
- Country
- NB United States
- FTRE United States
- Employees
- NB N/A
- FTRE N/A
- Industry
- NB Metal Mining
- FTRE Medical Specialities
- Sector
- NB Basic Materials
- FTRE Health Care
- Exchange
- NB Nasdaq
- FTRE Nasdaq
- Market Cap
- NB 930.8M
- FTRE 864.4M
- IPO Year
- NB N/A
- FTRE N/A
- Fundamental
- Price
- NB $6.08
- FTRE $11.95
- Analyst Decision
- NB Strong Buy
- FTRE Hold
- Analyst Count
- NB 4
- FTRE 9
- Target Price
- NB $5.75
- FTRE $13.06
- AVG Volume (30 Days)
- NB 13.8M
- FTRE 1.2M
- Earning Date
- NB 11-06-2025
- FTRE 11-05-2025
- Dividend Yield
- NB N/A
- FTRE N/A
- EPS Growth
- NB N/A
- FTRE N/A
- EPS
- NB N/A
- FTRE N/A
- Revenue
- NB N/A
- FTRE $2,759,900,000.00
- Revenue This Year
- NB N/A
- FTRE $0.47
- Revenue Next Year
- NB N/A
- FTRE N/A
- P/E Ratio
- NB N/A
- FTRE N/A
- Revenue Growth
- NB N/A
- FTRE N/A
- 52 Week Low
- NB $1.30
- FTRE $3.97
- 52 Week High
- NB $12.58
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- NB 39.55
- FTRE 63.92
- Support Level
- NB $6.89
- FTRE $9.52
- Resistance Level
- NB $8.16
- FTRE $10.74
- Average True Range (ATR)
- NB 0.87
- FTRE 0.74
- MACD
- NB -0.40
- FTRE 0.02
- Stochastic Oscillator
- NB 1.98
- FTRE 77.78
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.